SG10202003100XA - Bacteria Engineered to Reduce Hyperphenylalaninemia - Google Patents
Bacteria Engineered to Reduce HyperphenylalaninemiaInfo
- Publication number
- SG10202003100XA SG10202003100XA SG10202003100XA SG10202003100XA SG10202003100XA SG 10202003100X A SG10202003100X A SG 10202003100XA SG 10202003100X A SG10202003100X A SG 10202003100XA SG 10202003100X A SG10202003100X A SG 10202003100XA SG 10202003100X A SG10202003100X A SG 10202003100XA
- Authority
- SG
- Singapore
- Prior art keywords
- bacteria engineered
- hyperphenylalaninemia
- reduce
- reduce hyperphenylalaninemia
- engineered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
- C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03002—L-Amino-acid oxidase (1.4.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y403/00—Carbon-nitrogen lyases (4.3)
- C12Y403/01—Ammonia-lyases (4.3.1)
- C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562161137P | 2015-05-13 | 2015-05-13 | |
| US201562256052P | 2015-11-16 | 2015-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202003100XA true SG10202003100XA (en) | 2020-05-28 |
Family
ID=56117975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202003100XA SG10202003100XA (en) | 2015-05-13 | 2016-05-13 | Bacteria Engineered to Reduce Hyperphenylalaninemia |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US10610546B2 (en) |
| EP (2) | EP3294760B1 (en) |
| JP (3) | JP6843768B2 (en) |
| AU (2) | AU2016262569B9 (en) |
| BR (1) | BR112017024384A2 (en) |
| CA (1) | CA2985819A1 (en) |
| ES (1) | ES2881384T3 (en) |
| IL (2) | IL296538A (en) |
| PL (1) | PL3294760T3 (en) |
| SG (1) | SG10202003100XA (en) |
| WO (1) | WO2016183531A1 (en) |
| ZA (1) | ZA201707678B (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2865825T3 (en) | 2014-04-01 | 2021-10-18 | Rubius Therapeutics Inc | Methods and compositions for immunomodulation |
| US9688967B2 (en) | 2014-12-05 | 2017-06-27 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| US20160206666A1 (en) | 2014-12-22 | 2016-07-21 | Synlogic, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier |
| KR20200091499A (en) | 2015-05-06 | 2020-07-30 | 스니프르 테크놀로지스 리미티드 | Altering microbial populations & modifying microbiota |
| JP6843768B2 (en) | 2015-05-13 | 2021-03-17 | シンロジック オペレーティング カンパニー インコーポレイテッド | Bacteria engineered to reduce hyperphenylalanineemia |
| US11883439B2 (en) | 2015-05-13 | 2024-01-30 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
| EP3294757B1 (en) * | 2015-05-13 | 2023-12-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
| US11685925B2 (en) | 2015-10-30 | 2023-06-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
| PL3377518T3 (en) * | 2015-11-16 | 2022-09-26 | Synlogic Operating Company, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| US11208649B2 (en) | 2015-12-07 | 2021-12-28 | Zymergen Inc. | HTP genomic engineering platform |
| US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
| US11566238B2 (en) | 2016-12-15 | 2023-01-31 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating growth of a genetically modified gut bacterial cell |
| WO2018183685A1 (en) * | 2017-03-29 | 2018-10-04 | President And Fellows Of Harvard College | Methods of regulating gene expression in a cell |
| US20180362590A1 (en) * | 2017-04-14 | 2018-12-20 | Synthetic Genomics, Inc. | Polypeptides with type v crispr activity and uses thereof |
| AU2018290278B2 (en) * | 2017-06-21 | 2022-12-15 | Synlogic Operating Company, Inc. | Bacteria for the treatment of disorders |
| MY195280A (en) | 2017-09-08 | 2023-01-12 | New Portal Ltd | Nucleic Acid Systems That Enable Bacteria to Specifically Target Solid Tumors Via Glucose-Dependent Viability |
| US10849938B2 (en) | 2017-09-13 | 2020-12-01 | ZBiotics Company | Gene expression system for probiotic microorganisms |
| CN107904222B (en) * | 2017-11-30 | 2019-10-08 | 江南大学 | A kind of l-amino acid deaminase mutant and its construction method that thermal stability improves |
| WO2019113096A1 (en) * | 2017-12-05 | 2019-06-13 | BioPlx, Inc. | Methods and compositions to prevent microbial infection |
| US20220047654A1 (en) * | 2018-12-20 | 2022-02-17 | University Of South Carolina | Pharmabiotic treatments for metabolic disorders |
| EP3963046A1 (en) | 2019-04-29 | 2022-03-09 | Synlogic Operating Company, Inc. | Enumeration of genetically engineered microorganisms by live cell counting techniques |
| CA3142608A1 (en) | 2019-06-04 | 2020-12-10 | Cocoon Biotech Inc. | Silk-based products, formulations, and methods of use |
| CN114450403A (en) * | 2019-06-21 | 2022-05-06 | 银杏生物制品公司 | Biosynthesis of enzymes for use in the treatment of Maple Syrup Urine Disease (MSUD) |
| CN110257291B (en) * | 2019-06-25 | 2021-07-23 | 北京大学 | Achromobacter capable of tolerating nickel ion toxicity and application thereof |
| JP2023500563A (en) | 2019-09-27 | 2023-01-10 | イントレキソン アクトビオティクス エヌヴェー デー／ベー／アー プレシゲン アクトビオ | Celiac disease treatment |
| CN116249779A (en) | 2019-11-12 | 2023-06-09 | 阿克蒂姆治疗有限公司 | Immunostimulatory bacteria delivery platform and use thereof for delivering therapeutic products |
| EP4090773A2 (en) | 2020-01-17 | 2022-11-23 | Université catholique de Louvain | Genetically modified bacterium with altered envelop integrity and uses thereof |
| US20230105474A1 (en) * | 2020-02-25 | 2023-04-06 | Synlogic Operating Company, Inc. | Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof |
| BR112022018571A2 (en) | 2020-03-20 | 2022-11-01 | Synlogic Operating Co Inc | MICRO-ORGANISMS MANIPULATED TO REDUCE HYPERPHENYLALANINEMIA |
| WO2021207647A1 (en) * | 2020-04-09 | 2021-10-14 | Computational International LLC | Small molecule drugs as targeted therapeutics |
| EP4176053A2 (en) * | 2020-07-02 | 2023-05-10 | The Regents of the University of California | Persistent memory t-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways |
| AU2021324883A1 (en) | 2020-08-12 | 2023-03-23 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
| US20230414732A1 (en) * | 2020-11-10 | 2023-12-28 | Palena Therapeutics, Inc. | Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use |
| CA3200887A1 (en) | 2020-12-02 | 2022-06-09 | Michael James | Engineered microorganisms |
| CN112501098B (en) * | 2020-12-11 | 2023-01-03 | 上海陶宇晟生物技术有限责任公司 | Engineering probiotics with phenylalanine degrading capability |
| CN116847860A (en) | 2020-12-31 | 2023-10-03 | 同生运营公司 | Microorganisms engineered to alleviate hyperphenylalaninemia |
| CN112662606A (en) * | 2021-01-06 | 2021-04-16 | 中国科学院分子植物科学卓越创新中心 | Engineering probiotics for treating phenylketonuria |
| CN112662607A (en) * | 2021-01-07 | 2021-04-16 | 上海陶宇晟生物技术有限责任公司 | Engineering probiotics with surface display of phenylalanine ammonia lyase |
| CA3223905A1 (en) * | 2021-06-24 | 2022-12-29 | Aouatef Bellamine | Method to control administration of active substance to the digestive tract |
| WO2023086796A2 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| CN116836899A (en) * | 2022-03-02 | 2023-10-03 | 和度生物技术(上海)有限公司 | Engineering microorganism for treating hyperphenylalaninemia and application thereof |
| CN114717172B (en) * | 2022-03-21 | 2022-09-23 | 江南大学 | Escherichia coli for synthesizing L-valine and construction method and application thereof |
| CN116463362B (en) * | 2023-06-15 | 2023-09-19 | 中国中医科学院中药研究所 | Preparation method of cell division inhibitor |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| CN1154845A (en) | 1996-09-09 | 1997-07-23 | 首都医学院附属北京红十字朝阳医院 | Genetic engineering fungus oral prepration capable of expressing active phenylalanine deaminase |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| WO2000032748A1 (en) | 1998-12-02 | 2000-06-08 | Trustees Of Boston University | Gene networks for control of gene expression |
| EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
| JP4452914B2 (en) | 2003-09-08 | 2010-04-21 | 味の素株式会社 | Novel transporter protein |
| TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| US9084434B2 (en) | 2006-09-27 | 2015-07-21 | Little Calumet Holdings Llc | Probiotic oral dosage forms |
| US20100297249A1 (en) | 2007-07-05 | 2010-11-25 | North-West University | Enhancement of the efficacy of therapeutic proteins |
| CN101586111B (en) * | 2008-05-22 | 2012-03-07 | 北京三元基因工程有限公司 | Method for preparing product of active lactic acid galactococcus |
| DK3181682T3 (en) | 2008-09-29 | 2021-07-05 | Intrexon Actobiotics Nv | REDUCED COLONIZATION OF MICROBES ON THE MUCKINS |
| US8129170B1 (en) | 2010-12-06 | 2012-03-06 | E.I. Du Pont De Nemours And Company | Recombinant bacteria having the ability to metabolize sucrose |
| US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
| US9017961B2 (en) | 2012-03-05 | 2015-04-28 | E.I. Du Pont De Nemours And Company | Recombinant bacteria comprising novel sucrose transporters |
| WO2013192543A2 (en) * | 2012-06-22 | 2013-12-27 | Phytogene, Inc. | Enzymes and methods for styrene synthesis |
| AU2013295621A1 (en) | 2012-07-27 | 2015-03-12 | University Of North Texas | Genetically modified probiotic for the treatment of phenylketonuria (PKU) disease |
| WO2014066945A1 (en) * | 2012-11-01 | 2014-05-08 | The Sydney Children's Hospital Network (Randwick & Westmead) | Genetically-modified probiotic for treatment of phenylketonuria |
| AU2014225717B2 (en) | 2013-03-07 | 2019-01-17 | President And Fellows Of Harvard College | Compositions and methods for bacterial delivery of polypeptides |
| CA2969724A1 (en) * | 2014-12-05 | 2016-06-09 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| US9688967B2 (en) | 2014-12-05 | 2017-06-27 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| EP3294757B1 (en) | 2015-05-13 | 2023-12-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
| JP6843768B2 (en) | 2015-05-13 | 2021-03-17 | シンロジック オペレーティング カンパニー インコーポレイテッド | Bacteria engineered to reduce hyperphenylalanineemia |
| AU2016276973B2 (en) * | 2015-06-10 | 2022-09-01 | Synlogic Operating Company, Inc. | Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid |
| WO2016210373A2 (en) | 2015-06-24 | 2016-12-29 | Synlogic, Inc. | Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof |
| US20170216370A1 (en) | 2015-07-31 | 2017-08-03 | Synlogic, Inc. | Bacteria engineered to treat disorders involving propionate catabolism |
-
2016
- 2016-05-13 JP JP2017559428A patent/JP6843768B2/en active Active
- 2016-05-13 BR BR112017024384A patent/BR112017024384A2/en active Search and Examination
- 2016-05-13 SG SG10202003100XA patent/SG10202003100XA/en unknown
- 2016-05-13 EP EP16728448.8A patent/EP3294760B1/en active Active
- 2016-05-13 CA CA2985819A patent/CA2985819A1/en active Pending
- 2016-05-13 PL PL16728448T patent/PL3294760T3/en unknown
- 2016-05-13 WO PCT/US2016/032562 patent/WO2016183531A1/en active Application Filing
- 2016-05-13 US US15/154,934 patent/US10610546B2/en active Active
- 2016-05-13 AU AU2016262569A patent/AU2016262569B9/en active Active
- 2016-05-13 EP EP21156322.6A patent/EP3882259A1/en active Pending
- 2016-05-13 IL IL296538A patent/IL296538A/en unknown
- 2016-05-13 US US15/301,324 patent/US10195234B2/en active Active
- 2016-05-13 ES ES16728448T patent/ES2881384T3/en active Active
- 2016-05-13 US US15/319,564 patent/US9889164B2/en active Active
- 2016-09-08 US US15/260,211 patent/US9943555B2/en active Active
-
2017
- 2017-11-12 IL IL255616A patent/IL255616B2/en unknown
- 2017-11-13 ZA ZA2017/07678A patent/ZA201707678B/en unknown
- 2017-12-22 US US15/852,762 patent/US10933102B2/en active Active
-
2020
- 2020-02-12 US US16/788,458 patent/US20200246394A1/en active Pending
-
2021
- 2021-02-24 JP JP2021027597A patent/JP7245271B2/en active Active
- 2021-08-06 AU AU2021212141A patent/AU2021212141A1/en active Pending
-
2023
- 2023-03-10 JP JP2023037515A patent/JP2023085295A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201707678B (en) | Bacteria engineered to reduce hyperphenylalaninemia | |
| IL278150A (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| HK1257676A1 (en) | Engineered crispr-cas9 nucleases | |
| HK1252666A1 (en) | Antibodies to cd40 | |
| PL3377518T3 (en) | Bacteria engineered to reduce hyperphenylalaninemia | |
| HK1252613A1 (en) | 6-amino-quinoline-3-carbonitrils as cot modulators | |
| GB2541833B (en) | Improvements to implant surfaces | |
| GB201514489D0 (en) | Hyperphenylalaninemia | |
| GB201409541D0 (en) | Probiotic Bacteria | |
| GB201515330D0 (en) | Bioreactor condenser | |
| GB201408039D0 (en) | Culture dish | |
| GB201519450D0 (en) | Novel treatment | |
| GB2538045B (en) | Improvements to letter-plates | |
| HUE044168T2 (en) | Improved fermenter | |
| GB201514420D0 (en) | Bioreactor | |
| HK1253094A1 (en) | Multi-peptide composition | |
| GB201520827D0 (en) | Bioreactor | |
| GB201514734D0 (en) | Mechanical bioreactor | |
| GB2522473B (en) | Improvements to windposts | |
| GB201517420D0 (en) | Improvements to bedpans | |
| GB201518810D0 (en) | Bioreactor | |
| GB201517290D0 (en) | Bioreactor | |
| GB201521028D0 (en) | Improvements to Li-fi | |
| GB2520781B (en) | Improvements to hydro-turbines | |
| PL3137475T3 (en) | Purification of epidaunorubicin |